Israel vs South Korea: Statin use vs. average non-HDL cholesterol levels
Israel
3.4
in 2018
South Korea
3.4
in 2018
Israel rank
75th
South Korea rank
75th
Statin use vs. average non-HDL cholesterol levels over time
- Israel
- South Korea
How they compare
Israel currently reports 3.4 against 3.4 in South Korea, a difference of 0.
The two have swapped places 3 times across 39 shared years of data; in 1980 it was Israel ahead.
Israel ranks 75th and South Korea ranks 75th of 191 countries.
Across the 4 decades both report, Israel averaged higher in 3 and South Korea in 1.
Head to head by decade
| Decade | Israel | South Korea | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.53 | 3.56 | 0.97 | Israel |
| 1990s | 4.09 | 3.6 | 0.49 | Israel |
| 2000s | 3.66 | 3.56 | 0.1 | Israel |
| 2010s | 3.46 | 3.49 | 0.0333 | South Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Israel or South Korea?
- Israel, at 3.4 against 3.4 in South Korea as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Israel and South Korea?
- 0, with Israel ahead.
- How many years of comparable data are there for Israel and South Korea?
- 39 years are reported by both, from 1980 to 2018.
- How do Israel and South Korea rank globally for statin use vs. average non-hdl cholesterol levels?
- Israel ranks 75th and South Korea ranks 75th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.